Wellington Management Group
ADCT icon

Wellington Management Group’s ADC Therapeutics ADCT Stock Holding History

Wellington Management Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
234,355
+3,291
+1% +$9.6K ﹤0.01% 1882
2026
Q1 		$866K Buy
231,064
+18,149
+9% +$71.6K ﹤0.01% 1701
2025
Q4 		$752K Sell
212,915
-37,169
-15% -$151K ﹤0.01% 1765
2025
Q3 		$1M Buy
+250,084
New +$788K ﹤0.01% 1778
2025
Q1 		– Sell
-253,342
Closed -$504K – 1935
2024
Q4 		$504K Buy
253,342
+84,785
+50% +$222K ﹤0.01% 1831
2024
Q3 		$531K Buy
+168,557
New +$532K ﹤0.01% 1810

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wellington Management Group's ADCT Position: Q2 2026 in Review

Wellington Management Group increased its ADC Therapeutics (ADCT) stake by 1.4% in Q2 2026, buying an estimated $9.6K and bringing the position to 234,355 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #1882.

Wellington Management Group first reported a position in ADCT in Q3 2024 and has held it in 6 quarters since. The position peaked at $1M in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Wellington Management Group held 234,355 shares of ADC Therapeutics worth $251K as of Q2 2026.
  • Wellington Management Group bought 3,291 ADC Therapeutics shares in Q2 2026, an estimated $9.6K.
  • ADC Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1882 holding.
  • Wellington Management Group first reported a position in ADC Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Wellington Management Group's ADC Therapeutics position peaked at $1M in Q3 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.